Within psychiatry, neuromodulation has mainly been explored using a small group of intracerebral targets. This session explored some of the other psychiatric conditions for which neuromodulation is being studied with emphasis on new neuroanatomic targets and new therapy selection.
Roscoe Brady
Kelly R. Bijanki, PhD
Despite recent advances in the scope and breadth of neuromodulation treatments, often times access continues to be limited. Many referring providers are not knowledgeable about the treatments available and many patients, especially those in underserved and rural communities, are statistically undertreated. During this session, we will discuss innovations in education both of neuromodulators, front line providers, and patients in hopes to increase global access to new, groundbreaking neuromodulation therapies.
Spinal cord stimulation (SCS) mediates analgesia by modulating spinal cord circuits. Multiple lines of evidence obtained from animal models suggest that SCS augments inhibition, decreases excitability, and reverses pathological states. This session will cover the latest research describing the effects of SCS on spinal networks
Yun Guan, MD, PhD
While significant advancements in neuromodulation have created to improved patient outcomes for an expanded number of painful conditions, conditions that may be managed primarily by non pain specialists. The limited implementation and uptake of these treatments by referring providers in non-pain care specialties impacts patient access to these high impact treatments. Illustrating the gaps and barriers that impact access enables strategic development aimed at accelerating uptake of these treatments at the population and health care ecosystem level.